


REMARKS

In Applicants response filed January 5, 2004, on page 16, paragraph 1, line 3, first sentence, reads "CDRs that do not translate into an antibody binding to an epitope with the binding properties as defined in claims 54 and 77, are within the claimed invention." It was Applicants intention to state that CDRs that do not translate into an antibody binding to an epitope with the binding properties as defined in claims 54 and 77, are not within the claimed invention.

This Amendment is a supplement to the Amendment and Response filed on January 5, 2004 in which Applicants are hereby correcting a typographical error. Please note that the correction does not add any new matter to the application.

The Commissioner is authorized to charge any deficiencies in fees or to credit any overpayments to counsel's Deposit Account 19-2380.

Respectfully submitted,



Jeffrey A. Lindeman
Registration No. 34,658

NIXON PEABODY LLP
Suite 900, 401 9th Street, N.W.
Washington, D.C. 20004-2128
(202) 585-8000